New hope from an old drug: Fighting alzheimer's disease with the cancer drug bexarotene (targretin)

Rejuvenation Research

Volumn 16, Issue 6, 2013, Pages 524-528

  Aicardi, Giorgio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BEXAROTENE; HIGH DENSITY LIPOPROTEIN; NOOTROPIC AGENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RESPONSE; HALF LIFE TIME; HIPPOCAMPUS; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; SINGLE DRUG DOSE; TREATMENT DURATION; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; REPRODUCIBILITY OF RESULTS; RETINOID X RECEPTORS; TETRAHYDRONAPHTHALENES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84890487073     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2013.1497     Document Type: Article

References (38)

1. Batsch NL, Mittelman MS. Alzheimer's Disease International - World Alzheimer Report 2012: ''Overcoming the stigma of dementia'' Available at: Www.alz.co.uk/research/WorldAlzheimerReport2012.pdf
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-356.
3. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44: 181-193.
4. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
5. Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, Wiltfang J, Serneels L, Karran E, Gijsen H, Schymkowitz J, Rousseau F, Broersen K, De Strooper B. The mechanism of c-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261-2274.
6. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS b-amyloid in Alzheimer's disease. Science 2010;330:1774.
7. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681-693.
8. Herz J, Hui DY. Lipoprotein receptors in the vascular wall. Curr Opin Lipidol 2006;15:175-181.
9. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171.
10. Lefebvre P, Benomar Y, Staels B. Retinoid X receptors: Common heterodimerization partners with distinct functions. Trends Endocrinol Metab. 2010;21:676-683.
11. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011;6:275-297.
12. Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets. 2011;15:1085-1097.
13. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-1506.
14. Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on ''ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models.'' Science 2013; 340:924-c.
15. Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS. Comment on ''ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models.'' Science 2013;340:924-f.
16. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B. Comment on ''ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models.'' Science 2013;340:924-e.
17. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM. Comment on ''ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models.'' Science 2013;340:924-d.
18. Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA. Response to comments on ''ApoE-directed therapeutics rapidly clear b-amyloid and reverse deficits in AD mouse models.'' Science. 2013;340:924-g.
19. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2005;25:8898-8902.
20. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 2010;30:11157-11166.
21. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452-457.
22. Kumar A. Long-term potentiation at CA3-CA1 hippocampal synapses with special emphasis on aging, disease, and stress. Front Aging Neurosci 2011;3:7(1-20).
23. Balietti M, Tamagnini F, Fattoretti P, Burattini C, Casoli T, Platano D, Lattanzio F, Aicardi G. Impairments of synaptic plasticity in aged animals and in animal models of Alzheimer's disease. Rejuvenation Res 2012;15:235-238.
24. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006; 52:831-843.
25. Tamagnini F, Burattini C, Casoli T, Balietti M, Fattoretti P, Aicardi G. Early impairment of long-term depression in the perirhinal cortex of a mouse model of Alzheimer's disease. Rejuvenation Res 2012;15:231-234.
26. Tamagnini F, Barker G, Warburton EC, Burattini C, Aicardi G, Bashir ZI. Nitric oxide-dependent long-term depression but not endocannabinoid-mediated long-term potentiation is crucial for visual recognition memory. J Physiol 2013;591: 3963-3979.
27. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5161-5166.
28. Balietti M, Giorgetti B, Casoli T, Solazzi M, Tamagnini F, Burattini C, Aicardi G, Fattoretti P. Early selective vulnerability of synapses and synaptic mitochondria in the hippocampal CA1 region of the Tg2576 mouse model of Alzheimer's disease. J Alzheimers Dis 2013;34:887-896.
29. Platano D, Fattoretti P, Balietti M, Giorgetti B, Casoli T, Di Stefano G, Bertoni-Freddari C, Aicardi G. Synaptic remodeling in hippocampal CA1 region of aged rats correlates with better memory performance in passive avoidance test. Rejuvenation Res 2008;11:341-348.
30. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997;386:407-410.
31. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 2012;69:29-38.
32. FDA, Drug approval package, Targretin, 1999. www. access data.fda.gov/drugsatfda-docs/nda/99/21055-Targretin.cfm
33. FDA, Package insert, Targretin, 2003. www.accessdata.fda.gov/drugsatfda- docs/label/2003/021055s002lbl.pdf
34. Howell SR, Shirley MA, Grese TA, Neel DA, Wells KE, Ulm EH. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors. Drug Metab Dispos 2001;29:990-998.
35. Strittmatter WJ. Medicine. Old drug, new hope for Alzheimer's disease. Science 2012;335:1447-1448.
36. LaFerla FM. Preclinical success against Alzheimer's disease with an old drug. N Engl J Med 2012;367:570-572.
37. Lowenthal J, Hull SC, Pearson SD. The ethics of early evidence - preparing for a possible breakthrough in Alzheimer's disease. N Engl J Med 2012;367:488-490.
38. Royall DR. The ''ethics'' of evidence are not evidence of ethics. J Am Geriatr Soc 2013;61:661.